At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 3 enrolled
Drug / intervention
AB-101 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study to Investigate the Effect of AB-101 in Breast Cancer Survivors
In Brief
A Early Phase 1 clinical trial evaluating AB-101 and Placebo for Sexual Dysfunction and 6 related conditions. Completed, enrolled 3 participants across 1 site.
Detailed Summary
The purpose of this research study is to investigate the possibility that a topical drug could restore nipple sensitivity and improve sexual quality of life in breast cancer survivors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSexual Dysfunction, Sexual Arousal Disorder, Sexual Dysfunction, Physiological, Breast Cancer, Nipple Disorder, Neuropathy, Cancer of Breast
CountriesUnited States
Collaborators--
Timeline
Early Ph 1CompletedFinished
20192020202120222023202420252026
Enrollment StartJul 2018
First PostedJul 2018
Primary CompletionOct 2019
TodayJul 2026
First PostedJul 19, 2018
Enrollment StartJul 9, 2018
Primary CompletionOct 12, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 8.0 years ago
Interventions
AB-101drug
Apply approximately 1 hour prior to sexual activity
Placebodrug
Apply approximately 1 hour prior to sexual activity